B Group, Inc. - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 17, 2026, for the 2025 Q4 period, B Group, Inc. held in its portfolio 16 assets valued at $135,434,612 (i.e. $135.44M).

The most valuable assets in the portfolio included: ADMA BIOLOGICS INC ($44.83M), CELLECTIS S A ($15.88M), and PALISADE BIO INC ($10.58M).

The chart below shows the top 10 valuable assets, and the table below shows the top 16 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in B Group, Inc. Portfolio

ADMA BIOLOGICS INC

CELLECTIS S A

PALISADE BIO INC

TAYSHA GENE THERAPIES INC

PRAXIS PRECISION MEDICINES I

SIGHT SCIENCES INC

ZAI LAB LTD

STRUCTURE THERAPEUTICS INC

ASSEMBLY BIOSCIENCES INC

IOVANCE BIOTHERAPEUTICS INC

B Group, Inc. - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
ADMA BIOLOGICS INC	2457542	44825566	COM
CELLECTIS S A	3281501	15882465	SPON ADS
PALISADE BIO INC	4500000	10575000	COM
TAYSHA GENE THERAPIES INC	1800556	9903058	COM SHS
PRAXIS PRECISION MEDICINES I	33237	9796273	COM NEW
SIGHT SCIENCES INC	920000	7295600	COM
ZAI LAB LTD	400000	7056000	ADR
STRUCTURE THERAPEUTICS INC	90000	6259500	SPONSORED ADS
ASSEMBLY BIOSCIENCES INC	175706	5975761	COM NEW
IOVANCE BIOTHERAPEUTICS INC	1500000	4095000	COM
SPYRE THERAPEUTICS INC	100000	3276000	COM NEW
AURA BIOSCIENCES INC	572576	3120539	COM
ULTRAGENYX PHARMACEUTICAL IN	135000	3105000	COM
ORUKA THERAPEUTICS INC	75000	2273250	COM
APOGEE THERAPEUTICS INC	20000	1509600	COM
REPLIMUNE GROUP INC	50000	486000	COM